PMC8482707_01
(Patient 1) (a) Contrast-enhanced chest CT prior and best response to treatment. (b) Hematoxylin and eosin-stained section of lymph node biopsy specimen. (c) PD-L1 protein expression assessed by immunohistochemistry.
10.1177_20406223211047306-fig1.jpg
PMC8482707_01_10.1177_20406223211047306-fig1.jpg
fig1-20406223211047306
Chest computed tomography (CT) revealed a 3.5 x 3.0 cm left lung mass (Figure 1(a)) as well as mediastinal, and supraclavicular lymphadenopathy. Biopsies of the supraclavicular masses showed lung squamous cell carcinoma (Figure 1(b)). The PD-L1 expression (tumor proportion score, TPS) was negative (Figure 1(c)). There was a 70% local tumor reduction based on contrast-enhanced CT analysis (Figure 1(a)).
PMC8482707_02
(Patient 2) (a) Contrast-enhanced chest CT prior and best response to treatment. (b) Hematoxylin and eosin-stained section of lung lesion biopsy specimen. (c) PD-L1 protein expression assessed by immunohistochemistry.
10.1177_20406223211047306-fig2.jpg
PMC8482707_02_10.1177_20406223211047306-fig2.jpg
fig2-20406223211047306
CT revealed a 4.5 x 3.3 cm right lung mass (Figure 2(a)) as well as mediastinal lymphadenopathy. Biopsies of the lung showed lung squamous cell carcinoma (Figure 2(b)). The PD-L1 expression (TPS) was negative (Figure 2(c)). One month after the combination therapy, the patient was deemed to show a stable disease (SD) on August 2018 (Figure 2(a)).
PMC8482707_03
(Patient 3) (a) Contrast-enhanced chest CT prior and best response to treatment. (b) Hematoxylin and eosin-stained section of lung lesion biopsy specimen. (c) PD-L1 protein expression assessed by immunohistochemistry.
10.1177_20406223211047306-fig3.jpg
PMC8482707_03_10.1177_20406223211047306-fig3.jpg
fig3-20406223211047306
CT revealed a 5.5 x 3.6 cm right hilar mediastinum mass (Figure 3(a)). Bronchoscopy biopsy of the lung showed lung squamous cell carcinoma (Figure 3(b)). The PD-L1 expression (TPS) was 30% (Figure 3(c)). There was a 80% local tumor reduction based on contrast-enhanced CT analysis (Figure 3(a)).